<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - ESOMEPRAZOLE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>ESOMEPRAZOLE</h1>

        <p><a href="../drugClass/PHP34658.html">PROTON PUMP INHIBITORS</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">NSAID-associated gastric ulcer</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                20 mg once daily for 4&#8211;8 weeks.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                20 mg daily continue until oral administration possible, injection to be given over at least 3 minutes.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of NSAID-associated gastric ulcer in patients with an increased risk of gastroduodenal complications who require continued NSAID treatment</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                20 mg daily.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                20 mg daily continue until oral administration possible, injection to be given over at least 3 minutes.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Gastro-oesophageal reflux disease (in the presence of erosive reflux oesophagitis)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 40 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed or symptoms persist; maintenance 20 mg daily.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                40 mg daily continue until oral administration possible, injection to be given over at least 3 minutes.</li>
              <li class="dose child"><strong>For children 1&#8211;11 years (body-weight 10&#8211;19 kg)</strong><br/>
                10 mg once daily for 8 weeks.</li>
              <li class="dose child"><strong>For children 1&#8211;11 years (body-weight 20 kg and above)</strong><br/>
                10&#8211;20 mg once daily for 8 weeks.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 40 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed or symptoms persist; maintenance 20 mg daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Symptomatic treatment of gastro-oesophageal reflux disease (in the absence of oesophagitis)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                20 mg once daily for up to 4 weeks, then 20 mg daily if required.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                20 mg once daily continue until oral administration possible, injection to be given over at least 3 minutes.</li>
              <li class="dose child"><strong>For children 1&#8211;11 years (body-weight 10 kg and above)</strong><br/>
                10 mg once daily for up to 8 weeks.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                20 mg once daily for up to 4 weeks, then 20 mg daily if required.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Zollinger&#8211;Ellison syndrome</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 40 mg twice daily, adjusted according to response; usual dose 80&#8211;160 mg daily, daily dose above 80mg should be given in 2 divided doses.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Severe peptic ulcer bleeding (following endoscopic treatment)</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 80 mg, to be given over 30 minutes, then (by continuous intravenous infusion) 8 mg/hour for 72 hours, then (by mouth) 40 mg once daily for 4 weeks.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication"><ph outputclass="organism"> <i>Helicobacter pylori</i> </ph> eradication in combination with clarithromycin and amoxicillin or metronidazole</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                20 mg twice daily.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises caution&#8212;no information available.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">In adults</h3>
              <p>In severe hepatic impairment max. 20&#8239;mg daily.</p><p>Severe peptic ulcer bleeding in severe hepatic impairment, initial intravenous infusion of 80&#8239;mg, then by continuous intravenous infusion, 4&#8239;mg/hour for 72 hours.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">In children</h3>
              <p>1&#8211;11 years max. 10&#8239;mg daily in severe impairment.</p><p>12&#8211;18 years max. 20&#8239;mg daily in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <p>Manufacturer advises caution in severe renal insufficiency.</p>
            </section>
      </section>



      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For<i>intravenous infusion</i> (<i>Nexium</i>
            <sup>
            <tm tmtype="reg"/>
            </sup>), give continuously <i>or</i> intermittently in Sodium Chloride 0.9%; reconstitute 40&#8211;80&#8239;mg with up to 100&#8239;ml infusion fluid; for intermittent infusion, give requisite dose over 10&#8211;30 minutes; stable for 12 hours in Sodium Chloride 0.9%.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous infusion</i>, dilute reconstituted solution to a concentration not exceeding 800&#8239;micrograms/mL with Sodium Chloride 0.9%; give over 10&#8211;30 minutes.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Do not chew or crush capsules; swallow whole <i>or</i> mix capsule contents in water and drink within 30 minutes.</p><p>Do not crush or chew tablets; swallow whole <i>or</i> disperse in water and drink within 30 minutes.</p><p>Disperse the contents of each sachet of gastro-resistant granules in approx. 15&#8239;mL water. Stir and leave to thicken for a few minutes; stir again before administration and use within 30 minutes; rinse container with 15&#8239;mL water to obtain full dose.</p><p>For administration through a gastric tube, consult product literature.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Counselling on administration of gastro-resistant capsules, tablets, and granules advised.</p>
            </section>
      </section>






      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Tablets and capsules not licensed for use in children 1&#8211;12 years.</p>
            </section>
      </section>










      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of ESOMEPRAZOLE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,

            <div id="PHP75597"><a href="../medicinalForm/PHP75597.html" data-target="#PHP75597" data-action="load">Gastro-resistant tablet</a></div>
            <div id="PHP75908"><a href="../medicinalForm/PHP75908.html" data-target="#PHP75908" data-action="load">Gastro-resistant capsule</a></div>
            <div id="PHP75829"><a href="../medicinalForm/PHP75829.html" data-target="#PHP75829" data-action="load">Gastro-resistant granules</a></div>
            <div id="PHP75675"><a href="../medicinalForm/PHP75675.html" data-target="#PHP75675" data-action="load">Powder for solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
